Reported 2 days ago
Citizens JMP analyst Silvan Tuerkcan has reaffirmed a Buy rating for IDEAYA Biosciences (NASDAQ:IDYA) with a price target of $45, noting the company's promising developments, particularly in their lead asset darovasertib for uveal melanoma. J.P. Morgan also supports this outlook with a Buy rating and a $74 target, highlighting potential valuable updates in multiple treatment settings. While IDEAYA presents investment potential, analysts suggest some AI stocks may offer higher upside with lower risks.
Source: YAHOO